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Schizophrenia is a complex disorder, caused by both genetic and environmental factors 
and their interactions. Research on pathogenesis has traditionally focused on 
neurotransmitter systems in the brain, particularly those involving dopamine. 
Schizophrenia has been considered a separate disease for over a century, but in the 
absence of clear biomarkers, diagnosis has historically been based on signs and 
symptoms. A fundamental message emerging from genome-wide association studies 
(GWASs) of copy number variations (CNVs) associated with the disease is that its 
genetic basis does not necessarily conform to classical nosological disease boundaries. 
Certain CNVs confer not only high relative risk of schizophrenia but also of other 
psychiatric disorders1-3. The structural variations associated with schizophrenia can 
involve several genes and the phenotypic syndromes, or the “genomic disorders“, have 
not yet been characterized4.  
Single nucleotide polymorphism (SNP)-based GWASs with the potential to 
implicate individual genes in complex diseases may reveal underlying biological 
pathways. In the present study we combined SNP data from several large genome-wide 
scans and followed up the most significant association signals. We found significant 
association with several markers spanning the MHC region on 6p22.1-22.3, a marker 
located upstream of the neurogranin gene (NRGN) on 11q24.2 and a marker in intron 
four of transcription factor 4 (TCF4) on 18q21.2. Our findings implicating the MHC region 
are consistent with an immune component to schizophrenia risk, while the association 
with NRGN and TCF4 points to perturbation of pathways involved in brain development, 
memory and cognition. 
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To begin our search for sequence variants associated with schizophrenia, we 
performed a genome-wide scan of 2,663 schizophrenia cases and 13,498 controls from 
eight European locations (England, Finland/Helsinki, Finland/Kuusamo, Germany/Bonn, 
Germany/Munich, Iceland, Italy and Scotland; collectively called SGENE-plus) using the 
Illumina HumanHap300 and HumanHap550 BeadChips. In total, 314,868 SNPs meeting 
our quality control criteria were included in an allelic association analysis. To adjust for 
relatedness and potential population stratification, genomic control was used. 
None of the markers gave P values smaller than our genome-wide significance 
threshold of 0.05/314,868, or approximately 1.6 x 10-7 (see Supplementary Figure 1 for 
a quantile-quantile plot and Supplementary Table 1 for markers with the smallest P 
values). Next, we combined findings from our top 1,500 markers with results for these 
same markers (or surrogates for them) from both the International Schizophrenia 
Consortium5 (ISC; excluding the Scottish samples overlapping with samples in our 
study, 2,602 cases / 2,885 controls) and the European-American portion of the 
Molecular Genetics of Schizophrenia6 (MGS; 2,687 cases / 2,656 controls) study. 
Twenty-five of our top 1,500 markers (or 18 counting very strongly correlated (r2 > 0.8) 
markers only once) had P values less than 1 x 10-5 in the combined results 
(Supplementary Table 2). These top markers were followed up in as many as 4,999 
cases and 15,555 controls from four sets of additional samples from Europe (set 1: 715 
cases and 3,634 controls from the Netherlands; set 2: 3,330 cases and 6,892 controls 
from Denmark/Aarhus, Denmark/Copenhagen, Germany/Bonn, Germany/Munich, 
Hungary, the Netherlands, Norway, Russia and Sweden; set 3: 287 cases and 3,987 
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controls from Finland; set 4: 667 cases and 1,042 controls from Spain/Santiago and 
Spain/Valencia) (Supplementary Table 3). 
Three markers, all in the extended major histocompatibility complex (MHC) region 
on the short arm of chromosome 6, were genome-wide significant in the combination of 
SGENE-plus and the follow-up samples described above (Table 1). In addition, four 
other markers, two in the MHC region, one at 11q24.2 and one at 18q21.2, were 
genome-wide significant when results from ISC and MGS were included (Table 1).  
In the MHC region on chromosome 6p22.1-22.3, the five genome-wide significant 
markers (P ranging from 1.1 x 10-9 to 1.4 x 10-12 in all samples combined) have risk 
alleles with average control frequencies between 78% and 92% (Table 1). Combined 
odds ratios (ORs) for the markers range from 1.15 to 1.24 (Table 1) with no significant 
heterogeneity between the study groups (P > 0.25, Supplementary Table 4). For all of 
the markers, the multiplicative model for risk provides an adequate fit (P > 0.62).   
Despite spanning about five megabases (Mb), the five chromosome 6p markers 
cover only about 1.4 centimorgans (cM) and substantial linkage disequilibrium (LD) 
exists between them (Supplementary Table 5). The association of rs6932590 (the most 
significant marker), however, cannot account for all of the association of the four 
remaining markers (Supplementary Table 6). Most notably, conditional on rs6932590, 
rs3131296 has an association P value of 3.4 x 10-6, suggesting that rs3131296 may be 
capturing a second susceptibility variant or that both rs6932590 and rs3131296 are 
correlated with a third, higher risk, variant not examined here. 
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To examine association of the genome-wide significant SNPs in the 5 Mb region 
on 6p22.1-22.3 with classical human leukocyte antigen (HLA) alleles, long-range 
phasing haplotypes7  tagging the major alleles at the HLA-A, HLA-B, HLA-C, HLA-
DRB1, HLA-DQA1 and HLA-DQB1 loci in Icelanders were used. Only rs3131296 shows 
substantial (r2 > 0.5) correlation with any of the classical HLA alleles tested; this marker 
has an r2 of 0.86 with DRB1*03 and an r2 of 0.81 with HLA-B*08. Simplified tags for 
these two classical alleles, appropriate for the European samples of SGENE-plus, had 
effects that were not statistically distinguishable from the effect of rs3131296. In the 
case of both DRB1*03 and HLA-B*08, the classical HLA allele is paired with the 
protective allele of rs3131296, making the results described here consistent with the 
under-transmission of DRB1*03 to schizophrenic offspring reported by Li et al.8  
Many autoimmune and infectious diseases have been associated with DRB1*03 
and, indeed, inspection of top MHC region SNPs from recent genome-wide association 
scans of three of these, type I diabetes (T1D)9, celiac disease (CD)10 and systemic lupus 
erythematosus11, reveals, for each disease, SNPs having a HapMap CEU r2 of at least 
0.73 with rs3131296. For all of the diseases, the allele protective from schizophrenia is 
associated with the allele at-risk for the autoimmune disease. This reciprocal association 
may, at least in part, explain the recently reported inverse association between T1D and 
schizophrenia12,13. A positive association, however, has been described for CD and 
schizophrenia12; if this positive association has a genetic basis, it must be the result of 
associations at variants other than the one described here. 
10 
 
Schizophrenia patients are more likely, compared to the general population, to 
have been born in the winter or the spring. Although infections such as influenza and 
measles have been proposed as a possible mechanism for this distortion, a clear 
association between infectious agents and schizophrenia has not been demonstrated. 
The association with the MHC region reported here supports a role for infection but, as 
many non-immune related genes are also found in the extended MHC region, it does not 
provide strong evidence. Based on  the 3,130 schizophrenia patients for which month of 
birth information was available, no significant difference in the frequency of the top SNPs 
from the MHC region according to season of birth (winter/spring versus summer/fall) was 
identified (P > 0.29). 
The MHC region has long been postulated to harbor variants conferring risk of 
schizophrenia, both because of evidence for linkage in the region14 and because of the 
suggested involvement of infection. Association studies of variants from the MHC region 
to date, however, have had modest sample sizes and therefore have lacked power to 
detect effects similar to those described here. 
 
The genome-wide significant marker (P = 2.4 x 10-9) at 11q24.2, rs12807809, has 
an average risk allele control frequency of 83% and a combined OR of 1.15 (Table 1) 
with no significant OR heterogeneity between the study groups (P = 0.74, 
Supplementary Table 4). The multiplicative model provides an adequate fit (P = 0.18). 
This marker is 3,457 bases upstream of neurogranin (NRGN). NRGN has previously 
been reported as associated in males with schizophrenia in a small Portuguese series15 
although the associated SNP in that paper, rs7113041,  is not closely correlated with the 
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SNP reported here (HapMap CEU r2=0.11). Furthermore, reduced NRGN immuno-
reactivity has been observed in prefrontal areas 9 and 32 of postmortem schizophrenia 
brains16. NRGN is expressed exclusively in brain, especially in dendritic spines, with 
expression directly controlled by thyroid hormone17. It is therefore possible that the 
psychotic and cognitive features associated with thyroid dysfunction, may in part be 
mediated through dysregulation of NRGN gene expression.  
NRGN encodes a postsynaptic protein kinase substrate that binds calmodulin 
(CaM) in the absence of calcium;  it is abundantly expressed in brain regions important 
for cognitive functions, and is especially enriched in CA1 pyramidal neurons in the 
hippocampus18. The main function of NRGN may be to act as a CaM reservoir, 
regulating its availability in the postsynaptic compartment. Glutamate stimulation of N-
methyl-d-aspartate (NMDA) receptors results in Ca2+ influx to the neuron, NRGN 
oxidation and release of CaM19. The consequent activation of postsynaptic 
calcium/calmodulin- dependent protein kinase II (CaMKII) by CaM results in a sustained 
strengthening of synaptic connections; conversely CaM activation of calcineurin (PP2B) 
weakens these connections. CaMKII plays a major role in mediating the NMDA-receptor 
signaling involved in synaptic plasticity and formation of associative memories in the 
brain20. Impaired memory function is thought to be a core feature of the pathophysiology 
of schizophrenia21, especially affecting short term memory where CAMKII is thought to 
play a major role22. Glutamate stimulation of NMDA receptors results in Ca2+ influx to the 
neuron and in NRGN oxidation. Altered NRGN activity may therefore mediate the effects 
of NMDA hypofunction implicated in the pathophysiology of schizophrenia. 
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On 18q21.2, marker rs9960767 has a genome-wide significant P-value of 4.1 x 
10-9 (Table 1). The risk allele control frequency is about 6% and the OR is 1.23 with no 
significant OR heterogeneity between the study groups (P = 0.34, Supplementary 
Table 4). The multiplicative model gives an adequate fit (P = 0.81). Genome scan meta 
analysis of linkage studies of schizophrenia14 ranks the 18q21.1-qter ‘bin’ around 15th in 
the genome. TCF4, is essential for normal brain development23 and mutations in the 
gene were recently found to be responsible for Pitt Hopkins syndrome (PHS), an 
autosomal dominant neurodevelopmental disorder characterized by severe motor and 
mental retardation, microcephaly, epilepsy and facial dysmorphisms24. The phenotype 
need not be as extreme as PHS, a de novo translocation disrupting exon 4 of TCF4 was 
found in an individual with problems restricted to mental retardation alone25. Thus, it 
seems that variants in a single gene can be associated with a range of neuropsychiatric 
phenotypes including schizophrenia. This is in line with the range of phenotypes 
associated with CNVs recently associated with schizophrenia1-3. 
In addition to these three genome-wide significant loci, further putative 
susceptibility variants are highlighted by this study. For instance, in the set of 18 markers 
taken into follow-up studies, rs2312147 achieved a P value that was not far from our 
genome-wide significance threshold (Supplementary Table 3). As well, markers having 
P values in the combined SGENE-plus, ISC and MGS data set (Supplementary Table 
2) somewhat larger than the cutoff used here (1x10-5) can be investigated further. 
Intriguingly, these markers include rs6589386, which is located in an intergenic region 
upstream of DRD2, a candidate gene for schizophrenia. 
13 
 
Our findings demonstrating association with markers in the MHC region are 
consistent with previous reports suggesting immune system involvement in 
schizophrenia, while association with NRGN and TCF4 points more to perturbation of 
pathways involved in brain development and cognitive function, particularly memory. 
Impaired cognitive and memory functions are being recognized increasingly as core 
features of schizophrenia21 which are poorly addressed by current medications. The 
three common genetic variants we describe, which predispose to schizophrenia, have 
the potential to be translated into targets for the development of novel medications.  
 
 
 
METHODS SUMMARY 
Subjects. SGENE-plus, the genome-wide portion of the study, included 2,663 cases and 13,498 
controls from eight European locations - England, Finland/Helsinki, Finland/ Kuusamo, 
Germany/Bonn, Germany/Munich, Iceland, Italy and Scotland. Follow-up groups comprised 
4,999 cases and 15,555 controls from twelve European locations (Denmark/Aarhus, 
Denmark/Copenhagen, Finland, Germany/Bonn, Germany/Munich, Hungary, the Netherlands, 
Norway, Russia, Spain/Santiago, Spain/Valencia and Sweden). Cases were diagnosed with 
schizophrenia according to DSM-IV or ICD-10 criteria (see Supplementary Methods). 
Genotyping.  Genome-wide genotyping was carried out at deCODE, Duke University and the 
University of Bonn using either HumanHap300 or HumanHap550 BeadChips (Illumina). 
Individual genotyping was done via Centaurus assays at deCODE and multiplex PCR and 
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minisequencing assays, followed by MALDI-TOF mass spectrometry analysis in Spain and 
Finland.  
Statistical analysis. A likelihood procedure described previously was used for association 
analysis26. To correct for relatedness and potential population stratification, genomic control was 
used27. Within our study, samples were combined with the Mantel-Haenszel model28. Our results 
were merged with those of the ISC and MGS by computing weighted averages of Z scores (see 
full Methods online). 
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METHODS 
 
Genome-wide genotyping. SGENE was initially made up of 1,321 cases and 12,277 controls 
typed at deCODE Genetics using the Illumina HumanHap300 BeadChip. For SGENE-plus, an 
additional 859 cases and 854 controls typed at Duke University using either the Illumina 
HumanHap300 BeadChip or the Illumina HumanHap550 BeadChip as well as 483 cases and 
367 controls typed at the University of Bonn using the HumanHap550 BeadChip were also 
included. Samples were excluded if they were low-yield (low yield was defined as below 98% 
except for the samples typed at Duke in which case low-yield was below 96%), if they were 
duplicates of other samples included in the study, if they had a sex determined by X 
chromosome marker homozygosity different from their reported sex or if they were estimated to 
have less than 90% European ancestry by running STRUCTURE29 using the HapMap CEU, YRI 
and CHB/JPT individuals as reference samples. Of the 317,503 markers on the HumanHap300 
BeadChip, 2,635 were deemed unusable due to lack of polymorphism, severe deviation from 
Hardy-Weinberg equilibrium (P < 1 x 10-10), low yield (< 95% in either cases or controls) or allele 
frequency differences between the typing centers (P < 1 x 10-7) ; 314,868 markers, then, 
remained for analysis.  
Follow-up genotyping. Follow-up set 1 (715 cases; 3,634 controls) was genotyped at UCLA on 
the HumanHap550 BeadChip and at deCODE Genetics on the HumanCNV370 BeadChip. Only 
the markers shown in Supplementary Table 3, however, were used in this study. Follow-up set 2 
(3,330 cases; 6,892 controls) was genotyped at deCODE Genetics using Centaurus assays 
(Nanogen). Assay quality was evaluated by genotyping the CEU HapMap samples and 
comparing the results with the publicly released HapMap data.  Assays with a greater than 1.5% 
mismatch rate were not used. Follow-up set 3 (287 cases; 3,987 controls) was typed in Finland 
using the Sequenom MassArray iPLEX genotyping system, following the manufacturer’s 
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instructions (Sequenom Inc., San Diego, CA, USA). Briefly, the system involves multiplex PCR 
and mini-sequencing assays, followed by MALDI-TOF mass spectrometry analysis. Follow-up 
set 4 (667 cases; 1,042 controls) was typed at the Santiago de Compostela node of the Spanish 
National Genotyping Centre (www.cegen.org) using the Sequenom MassArray iPLEX 
genotyping system, following the manufacturer’s instructions (Sequenom Inc., San Diego, CA, 
USA). As a quality check, all clusters were manually inspected for accurate genotype 
assignment. In addition, 1781 genotypes were successfully assayed twice, with no discordant 
results.  
Association analysis. Association analysis was carried out using a likelihood procedure 
described in a previous publication implemented in NEMO software26. Allele-specific ORs and 
associated P-values were calculated assuming a multiplicative model for the two chromosomes 
of an individual. Association was tested using a standard likelihood ratio statistic that, if the 
subjects were unrelated, would have asymptotically a chi-square distribution with 1 degree of 
freedom under the null hypothesis. To correct for relatedness and potential population 
stratification in the genome-wide typed samples (SGENE-plus and follow-up set 1), genomic 
control was used27. Inflation factors, estimated by dividing the median of the 314,868 chi-square 
statistics by 0.6752, were 1.01, 1.03, 1.09, 1.05, 1.05, 1.19, 1.04 and 1.09 for the SGENE-plus 
England, Finland/Helsinki, Finland/Kuusamo, Germany/Bonn, Germany/Munich, Iceland, Italy 
and Scotland groups, respectively, and 1.08 for follow-up set 1. The inflation factor was large in 
Iceland because of the inclusion of close relatives in that data set. Both SGENE-plus and the 
follow-up samples were combined using the Mantel-Haenszel model28.  
Summary statistic combination. Combined P values for the SGENE-plus, ISC and MGS 
studies were calculated by summing Z scores with each group’s Z score multiplied by the 
inverse of that group’s standard error divided by the square root of the sum of the squared 
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inverse standard errors. Combined ORs were calculated by summing log ORs with each log OR 
weighted by the inverse of its variance.   
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Table 1.  Genome-wide significant association of seven markers with schizophrenia  
    
SGENE-plus1 
(2,663 cases /  
13,498 controls) 
 
Follow-up  
(4,999 cases /  
15,555 controls) 
SGENE-plus + 
Follow-up 
(7,662 cases / 
29,053 controls) 
S-p + F-u + ISC + MGS 
(12,951 cases / 
34,594 controls) 
 
 
Chr/Mb 
 
SNP[allele] 
 
Freq 
 
OR 
(95% CI) 
 
P value 
 
OR 
(95% CI) 
 
P value 
 
OR 
(95% CI) 
 
P value 
 
OR 
(95% CI) 
 
P value 
Region/ 
neighboring 
gene  
6/27.2 rs6913660[C]2,8 0.85 1.22 
(1.10,1.36) 
0.00023 1.11 
(1.04,1.19) 
0.0021 1.14 
(1.08,1.21) 
4.7x10-6 1.15 
(1.10,1.21) 
1.1x10-9 MHC/ 
HIST1H2BJ 
6/27.3 rs13219354[T]3,8 0.90 1.25 
(1.11,1.42) 
0.00043 1.19 
(1.08,1.30) 
0.00022 1.21 
(1.12,1.30) 
4.4x10-7 1.20 
(1.14,1.27) 
1.3x10-10 MHC/ 
PRSS16 
6/27.4 rs6932590[T]4,8 0.78 1.15 
(1.05,1.26) 
0.0024 1.17 
(1.10,1.25) 
4.9x10-7 1.17 
(1.11,1.23) 
4.4x10-9 1.16 
(1.11,1.21) 
1.4x10-12 MHC/ 
PRSS16 
6/28.4 rs13211507[T]5,8 0.92 1.24 
(1.08,1.42) 
0.0027 1.27 
(1.15,1.40) 
3.1x10-6 1.26 
(1.16,1.36) 
3.1x10-8 1.24 
(1.16,1.32) 
8.3x10-11 MHC/ 
PGBD1 
6/32.3 rs3131296[G]5,8 0.87 1.21 
(1.08,1.36) 
0.0011 1.20 
(1.11,1.30) 
5.3x10-6 1.21 
(1.13,1.29) 
2.1x10-8 1.19 
(1.13,1.25) 
2.3x10-10 MHC/ 
NOTCH4 
11/124.1 rs12807809[T] 0.83 1.19 
(1.08,1.32) 
0.00045 1.13 
(1.06,1.21) 
0.00022 1.15 
(1.09,1.22) 
5.0x10-7 1.15 
(1.10,1.20) 
2.4x10-9 NRGN 
18/51.3 rs9960767[C]678 0.056 1.30 
(1.11,1.51) 
0.0011 1.20 
(1.08,1.33) 
0.00044 1.23 
(1.13,1.34) 
2.2x10-6 1.23 
(1.15,1.32) 
4.1x10-9 TCF4 
Allelic OR and P values (two-sided) based on the multiplicative model are shown. Frequency is the average allelic 
control frequency in SGENE-plus. Mb is from the National Center for Biotechnology Information (NCBI) build 36. To 
combine the study groups within SGENE-plus and within the follow-up, the Mantel-Haenszel model was used. 
SGENE-plus and the follow-up sets were combined with ISC and MGS by summing weighted summary statistics (the 
Aberdeen samples were not included in the ISC results used). 1P values were adjusted using genomic control (see 
Methods) 2rs4452638 in ISC (HapMap CEU r2=0.866) 3rs4452638 in ISC (HapMap CEU r2=1) 4rs3800307 in ISC 
(HapMap CEU r2=0.843) 5rs13214023 in ISC (HapMap CEU r2=0.915) 6rs1150753 in ISC (HapMap CEU r2=1) 
7rs10401120 in ISC (HapMap CEU r2=0.867) 8imputed using MACH 1.0 in MGS 
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